Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors.

PubWeight™: 0.96‹?› | Rank: Top 15%

🔗 View Article (PMID 9818075)

Published in Ann Oncol on September 01, 1998

Authors

N Touroutoglou1, D Gravel, M N Raber, W Plunkett, J L Abbruzzese

Author Affiliations

1: Department of Gastrointestinal Medical Oncology and Digestive Diseases, University of Texas, M.D. Anderson Cancer Center, Houston, USA.

Articles by these authors

A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol (1991) 3.96

Action of 2',2'-difluorodeoxycytidine on DNA synthesis. Cancer Res (1991) 3.57

Superoxide dismutase as a target for the selective killing of cancer cells. Nature (2000) 3.44

The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res (1999) 3.36

Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol (1997) 2.75

Flow cytometry in clinical cancer research. Cancer Res (1983) 2.72

Plantarflexor weakness as a limiting factor of gait speed in stroke subjects and the compensating role of hip flexors. Clin Biomech (Bristol, Avon) (1999) 2.59

Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst (1991) 2.38

Constitutive Sp1 activity is essential for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma. Cancer Res (2001) 2.27

Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. Ann Surg Oncol (2001) 2.24

Cancer of the breast: a study of 1520 consecutive patients operated on between 1960 and 1980. Can J Surg (1991) 2.06

Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk Lymphoma (2002) 2.04

Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine. Cancer Res (1988) 2.03

Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV. J Clin Oncol (2004) 2.02

Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin. J Clin Oncol (1995) 1.89

Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2',2'-difluorodeoxycytidine. Mol Pharmacol (1990) 1.88

Adenovirus-mediated wild-type p53 tumor suppressor gene therapy induces apoptosis and suppresses growth of human pancreatic cancer [seecomments]. Ann Surg Oncol (1998) 1.78

Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst (1993) 1.77

The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere). Cancer Treat Rev (1993) 1.74

Analysis of the clinical factors determining natural and maximal gait speeds in adults with a stroke. Am J Phys Med Rehabil (1999) 1.74

DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clin Cancer Res (2001) 1.71

The need for standardized pathologic staging of pancreaticoduodenectomy specimens. Pancreas (1996) 1.68

Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. J Clin Oncol (1994) 1.64

Classification and regression tree analysis of 1000 consecutive patients with unknown primary carcinoma. Clin Cancer Res (1999) 1.60

Selective action of 3'-azido-3'-deoxythymidine 5'-triphosphate on viral reverse transcriptases and human DNA polymerases. J Biol Chem (1990) 1.60

A multispecialty approach to the diagnosis and management of pancreatic cancer. Am J Gastroenterol (2000) 1.58

Comprehensive criteria for assessing therapy-induced toxicity. Cancer Invest (1990) 1.57

Nucleoside analogs: molecular mechanisms signaling cell death. Oncogene (2008) 1.51

Pharmacologically directed design of the dose rate and schedule of 2',2'-difluorodeoxycytidine (Gemcitabine) administration in leukemia. Cancer Res (1990) 1.50

Deoxynucleotide pool depletion and sustained inhibition of ribonucleotide reductase and DNA synthesis after treatment of human lymphoblastoid cells with 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) adenine. Cancer Res (1996) 1.48

Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol (2001) 1.47

Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res (2000) 1.47

Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma. Clin Cancer Res (2001) 1.46

Carbapenem-resistant Gram-negative bacilli in Canada 2009-10: results from the Canadian Nosocomial Infection Surveillance Program (CNISP). J Antimicrob Chemother (2012) 1.45

Constitutive and inducible interleukin 8 expression by hypoxia and acidosis renders human pancreatic cancer cells more tumorigenic and metastatic. Clin Cancer Res (1999) 1.45

Maximal grip force in chronic stroke subjects and its relationship to global upper extremity function. Clin Rehabil (1999) 1.43

Regulation of vascular endothelial growth factor expression by acidosis in human cancer cells. Oncogene (2001) 1.41

Cellular elimination of 2',2'-difluorodeoxycytidine 5'-triphosphate: a mechanism of self-potentiation. Cancer Res (1992) 1.40

Survival of breast-cancer patients with previous or subsequent neoplasms. Can J Surg (1992) 1.39

Preoperative chemoradiation for adenocarcinoma of the pancreas: excessive toxicity of prophylactic hepatic irradiation. Int J Radiat Oncol Biol Phys (1995) 1.39

Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol (1993) 1.38

Gemcitabine: a modulator of intracellular nucleotide and deoxynucleotide metabolism. Semin Oncol (1995) 1.38

Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome. Leukemia (1996) 1.36

Preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for adenocarcinoma of the pancreatic head. Am J Surg (1996) 1.35

Induction of p21waf1 expression and growth inhibition by transforming growth factor beta involve the tumor suppressor gene DPC4 in human pancreatic adenocarcinoma cells. Cancer Res (1997) 1.34

Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. Br J Cancer (2005) 1.34

Saturation of 2',2'-difluorodeoxycytidine 5'-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemother Pharmacol (1991) 1.33

Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine. Br J Cancer (2009) 1.32

Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma. J Clin Oncol (1998) 1.29

Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood (1989) 1.29

A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma. Cancer (1996) 1.27

Docetaxel enhances tumor radioresponse in vivo. Clin Cancer Res (1997) 1.27

Thin-section contrast-enhanced computed tomography accurately predicts the resectability of malignant pancreatic neoplasms. Am J Surg (1994) 1.25

Major vascular resection as part of pancreaticoduodenectomy for cancer: radiologic, intraoperative, and pathologic analysis. J Gastrointest Surg (2000) 1.24

Detection of gas embolism by transesophageal echocardiography during laparoscopic cholecystectomy. Anesth Analg (1996) 1.23

2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine: a novel anticancer nucleoside analog that causes both DNA strand breaks and G(2) arrest. Mol Pharmacol (2001) 1.22

Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study. J Clin Oncol (1992) 1.22

On auxotrophy for pyrimidines of respiration-deficient chick embryo cells. Eur J Biochem (1984) 1.22

Differential incorporation of ara-C, gemcitabine, and fludarabine into replicating and repairing DNA in proliferating human leukemia cells. Blood (1997) 1.20

Fludarabine- and gemcitabine-induced apoptosis: incorporation of analogs into DNA is a critical event. Cancer Chemother Pharmacol (1995) 1.20

Evaluation of pre- and postoperative chemotherapy for resectable adenocarcinoma of the esophagus or gastroesophageal junction. J Clin Oncol (1990) 1.20

Aortoesophageal fistula: repair with transluminal placement of a thoracic aortic stent-graft. J Vasc Interv Radiol (1997) 1.20

Metabolism and actions of 2-chloro-9-(2-deoxy-2-fluoro-beta-D- arabinofuranosyl)-adenine in human lymphoblastoid cells. Cancer Res (1995) 1.19

Relative expression of E-cadherin and type IV collagenase genes predicts disease outcome in patients with resectable pancreatic carcinoma. Clin Cancer Res (1999) 1.18

Termination of DNA synthesis by 9-beta-D-arabinofuranosyl-2-fluoroadenine. A mechanism for cytotoxicity. J Biol Chem (1990) 1.17

Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2'-deoxyadenosine and 9-beta-D-arabinosyl-2-fluoroadenine. Blood (1993) 1.16

Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated RelA. Oncogene (1999) 1.15

S-Phase arrest by nucleoside analogues and abrogation of survival without cell cycle progression by 7-hydroxystaurosporine. Cancer Res (2001) 1.13

Enhancement of tumor radioresponse in vivo by gemcitabine. Cancer Res (1999) 1.11

Design and results of phase I cancer clinical trials: three-year experience at M.D. Anderson Cancer Center. J Clin Oncol (1996) 1.10

Interaction of p53 and DNA-PK in response to nucleoside analogues: potential role as a sensor complex for DNA damage. Cancer Res (2001) 1.09

Significance of peritoneal cytology in patients with potentially resectable adenocarcinoma of the pancreatic head. Surgery (1995) 1.09

Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy. Cancer Res (1987) 1.08

Ploidy, proliferative activity and estrogen receptor content in human breast cancer. Cytometry (1982) 1.07

Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions. Blood (1996) 1.06

Penetration of mouse fibroblasts by the 5'-phosphate of 9-beta-D-arabinofuranosyladenine and incorporation of the nucleotide into DNA. Proc Natl Acad Sci U S A (1974) 1.06

Unknown primary tumors metastatic to liver. J Clin Oncol (1998) 1.06

Two approaches that increase the activity of analogs of adenine nucleosides in animal cells. Cancer Res (1975) 1.06

Compound GW506U78 in refractory hematologic malignancies: relationship between cellular pharmacokinetics and clinical response. J Clin Oncol (1998) 1.06

Modulation of deoxycytidylate deaminase in intact human leukemia cells. Action of 2',2'-difluorodeoxycytidine. Biochem Pharmacol (1992) 1.06

Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma. J Clin Oncol (1994) 1.05

Phase II trial of ZD1694 (Tomudex) in patients with advanced pancreatic cancer. Invest New Drugs (1996) 1.05

In vitro and in vivo antitumor effect of the anti-CD26 monoclonal antibody 1F7 on human CD30+ anaplastic large cell T-cell lymphoma Karpas 299. Clin Cancer Res (2001) 1.05

Molecular regulation of constitutive expression of interleukin-8 in human pancreatic adenocarcinoma. J Interferon Cytokine Res (2000) 1.05

Modulatory activity of 2',2'-difluorodeoxycytidine on the phosphorylation and cytotoxicity of arabinosyl nucleosides. Cancer Res (1990) 1.05

Common bile duct exploration: the place of laparoscopic choledochotomy. Surg Laparosc Endosc (1994) 1.04

Cooperation between transcription factor AP-1 and NF-kappaB in the induction of interleukin-8 in human pancreatic adenocarcinoma cells by hypoxia. J Interferon Cytokine Res (1999) 1.04

Inhibition of RNA transcription: a biochemical mechanism of action against chronic lymphocytic leukemia cells by fludarabine. Leukemia (2000) 1.04

Efficacy of bevacizumab plus erlotinib for advanced hepatocellular carcinoma and predictors of outcome: final results of a phase II trial. Oncology (2012) 1.04

Toxicity and efficacy of concurrent gemcitabine and radiotherapy for locally advanced pancreatic cancer. Int J Pancreatol (2001) 1.03

Nucleotide requirements for the in vitro activation of the apoptosis protein-activating factor-1-mediated caspase pathway. J Biol Chem (2000) 1.03

Molecular epidemiology of vancomycin-resistant enterococcal bacteraemia: results from the Canadian Nosocomial Infection Surveillance Program, 1999-2009. J Antimicrob Chemother (2013) 1.03

Induction of apoptosis by gemcitabine. Semin Oncol (1995) 1.03

Prognostic factors in resectable pancreatic cancer: p53 and bcl-2. J Gastrointest Surg (2000) 1.02

Pharmacokinetics of nelarabine and 9-beta-D-arabinofuranosyl guanine in pediatric and adult patients during a phase I study of nelarabine for the treatment of refractory hematologic malignancies. J Clin Oncol (2000) 1.02

Saturation of ara-CTP accumulation during high-dose ara-C therapy: pharmacologic rationale for intermediate-dose ara-C. Semin Oncol (1987) 1.02